Amylyx Pharmaceuticals Inc Dossier - Source-backed chat

Amylyx Pharmaceuticals Inc

AMLXNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.25

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $29.10Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.7B

Enterprise Value $3.7B

Shares Outstanding 118M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Amylyx Pharmaceuticals has successfully transitioned its strategic focus to its high-potential endocrine and rare disease pipeline following the voluntary withdrawal of Relyvrio in early 2024. The company's investment thesis is now heavily anchored on avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 development for post-bariatric hypoglycemia (PBH). With enrollment complete in the pivotal LUCIDITY trial and topline data expected in Q3 2026, Amylyx is approaching a major clinical inflection point. Backed by a robust cash runway extending into 2028, the company is well-capitalized to fund operations through potential FDA approval and commercial launch in 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$27.50

High · most bullish analyst$40.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.0020%

The Phase 3 LUCIDITY trial fails to meet its primary endpoint or shows marginal efficacy that does not justify regulatory approval, forcing the discontinuation of the avexitide program in PBH. Consequently, the company is forced to pivot back to its early-stage pipeline (AMX0114 and AMX0318), which are years away from commercialization. Cash burn accelerates, and the stock trades down toward its liquidation value as investors discount the pipeline's viability.

Base CaseCentral scenario

$27.5050%

Matches the consensus mean

The Phase 3 LUCIDITY trial meets its primary composite endpoint of reducing Level 2 and Level 3 hypoglycemic events with a clean safety profile, though the effect size is slightly more conservative than earlier phase trials. Amylyx files its NDA in early 2027, leading to FDA approval and a commercial launch in late 2027 or early 2028. The company successfully targets high-expertise endocrinology centers to drive initial adoption. Cash reserves remain sufficient to fund operations into 2028 without requiring highly dilutive financing before the initial launch phase.

Bull CaseUpside scenario

$40.0030%

The Phase 3 LUCIDITY trial replicates the strong efficacy and safety profile seen in previous Phase 1 and Phase 2 trials, demonstrating a highly statistically significant reduction in Level 2 and Level 3 hypoglycemic events. Favorable data leads to rapid FDA approval under Breakthrough Therapy designation by late 2027. Commercial launch in 2027 successfully captures a significant portion of the estimated 160,000 U.S. patients living with PBH, supported by the adoption of a dedicated ICD-10 code in October 2026. Additionally, AMX0035 and AMX0114 deliver positive clinical readouts, establishing a diversified, high-value rare disease portfolio.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Lead asset avexitide addresses post-bariatric hypoglycemia (PBH), a high unmet medical need with no FDA-approved therapies and an estimated 160,000 U.S. patients.
Strong cash position of $279.8 million as of March 31, 2026, providing a runway into 2028 that fully funds operations through key Phase 3 readouts and potential commercialization.
Favorable regulatory designations, including FDA Breakthrough Therapy and Orphan Drug designations for avexitide, which streamline the path to potential approval.
Diversified clinical pipeline with AMX0035 showing positive Phase 2 data in Wolfram syndrome and AMX0114 advancing in ALS.

Key Investment Risks

High binary clinical trial risk, as the company's near-term valuation is heavily dependent on the Q3 2026 Phase 3 LUCIDITY readout.
Zero product revenue following the voluntary withdrawal of Relyvrio, resulting in ongoing quarterly net losses and cash burn.
Potential for future shareholder dilution under the filed shelf registration if clinical timelines are extended or commercialization costs exceed expectations.

Thesis Invalidation Triggers

Failure of the Phase 3 LUCIDITY trial to meet its primary composite endpoint of reducing Level 2 and Level 3 hypoglycemic events.
Unexpected safety or tolerability signals in the LUCIDITY trial or the Expanded Access Program that limit avexitide's clinical utility.
A significant acceleration in quarterly cash burn that shortens the cash runway to well before 2028, forcing highly dilutive capital raises.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.